Abstract
investigations. The daily dose of the b-blocker was already drug might be of particular benefit for the treatment taken at home at breakfast and the morning dose CsA was of renal transplant recipients. We therefore studied the administered in the ward after the first blood sample had influence of tertatolol on systemic and renal haemobeen drawn. A venous catheter was inserted in the forearm dynamics in CsA-treated renal transplant recipients. for continuous infusion of an inulin (polyfructosan; Inutest, For comparison the same patients were studied when Laevosan Gesellschaft, Linz, Austria) and para-amino-hipusing the b-blocker atenolol.
paric acid (PAH )-solution, as described before [13] . After a 90 min equilibration period three clearance periods of 45 min each were scheduled. Blood and urine samples were collected
Subjects and methods
at the beginning and end of the clearance periods. The patients remained supine except for spontaneous voiding. Mean arterial pressure (MAP) and heart rate (HR) were Patients monitored every 5 min with an automatic device (Dinamap, Critikon, FL, USA). During the measurements, diuresis was The study was approved by the hospital Ethics Committee maintained by an oral water load of 150 ml per 30 min. and all patients gave written informed consent before study entrance. Hypertensive renal transplant recipients (n=12) on CsA, already using atenolol, were recruited from our trans-Laboratory procedures plant population. The characteristics of the 12 participants are presented in Table 1 . In the seven patients treated with a PAH, inulin and creatinine concentrations in urine and combination of antihypertensive agents, all antihypertensive plasma samples were determined by standard techniques and drugs except atenolol were withdrawn at least 4 weeks before haematocrit was determined by routine Coulter counter. the start of the study. All participants had stable renal Whole blood CsA levels were measured with a monoclonal transplant function with a calculated Cockcroft creatinine antibody against the CsA parent molecule (Abbott TDX, clearance of at least 30 ml/min and stable CsA trough levels Abbott Laboratories, Chicago, USA). during the last 3 months preceding the study. The patients varied in original kidney diseases (two primary focal glom-
Calculations and statistical analysis
erulosclerosis, two undefined glomerulonephritis, three polycystic kidney disease, three chronic pyelonephritis, and two GFR was estimated by inulin clearance and effective RPF kidney diseases of unknown origin). Both native kidneys by PAH clearance. Plasma concentrations (P), urine concenwere still in situ in all patients except in one who had trations ( U ) and urine flow ( V ) were used to calculate the undergone unilateral nephrectomy before transplantation.
clearances (Cl ) of both substances according to the standard As immunosuppressive regimen three patients used CsA formula C1=UV/P. Filtration fraction (FF ) was calculated monotherapy and nine used CsA in combination with by GFR/RPF. Mean values of the three clearance periods prednisone in a daily dose of 11±2 mg (range 10-15 mg).
were used for further analysis. All values were adjusted to a standard body surface area of 1.73 m2. Mean arterial pressure
Study design
and heart rate were calculated as the mean of five Dinamap recordings in the middle of each clearance period.
All values This open study consisted of three consecutive treatment are expressed as means±SEM unless stated otherwise. periods of 4 weeks each, all periods ending with a renal Statistics were performed with the SAS system (SAS Institute function measurement. In the first 4 weeks patients were Inc, Cary, NC, USA). To compare the renal and systemic treated with atenolol 100 mg once daily, a dose equipotent haemodynamic results of the three treatment periods to 5 mg of tertatolol. Hereafter, a wash-out period was two-tailed paired Wilcoxon tests were used. P<0.05 was scheduled. In 1 week the atenolol dosage was tapered to considered to be statistically significant. zero. This was followed by a 3 week period without any antihypertensive treatment. The last 4 weeks the patients were treated with tertatolol 5 mg once daily. Patients were Results advised to take the b-blockers every morning at breakfast time.
During the wash-out period (without antihypertensive treatment) systolic blood pressure and diastolic presRenal function measurement sure by mercury sphygmomanometry were respectively 160±5 mm Hg and 106±3 mm Hg, the heart rate was Renal function measurements were performed in the morning 68±2 beats/min. The haemodynamic parameters as from 9.00 am until 2.00 pm. The patients were instructed to measured during the three study periods are given in refrain from smoking and coffee drinking during the last 8 h Table 2 . In comparison with the wash-out period heart and from alcohol during the last 24 h before the renal rate was lower during treatment with both atenolol and tertatolol (P<0.01). MAP was also lower during the b-blocker according to the original renal disease. changes in plasma renin activity and plasma aldosterone, and the increase of renal blood flow [12] . Plasma renin activity and plasma aldosterone both The four patients with glomerulonephritis as their decreased early after tertatolol infusion, whereas the original kidney disease had a higher MAP during the increase in renal blood flow was delayed. Furthermore, wash-out period than the patients with other kidney the results of studies using rat kidneys suggest that the diseases (141±2 mm Hg vs 120±1 mm Hg). They also renal vasodilation caused by tertatolol is related to showed a more striking decrease in MAP during b-its agonistic action on 5-HT1A receptors [16, 17] . blockade (mean decline 14±2 mm Hg in the glom-Intervention studies measuring the effects of CsA erulonephritis group vs 3±1 mm Hg in the remaining revealed various mediators which have been considered group, P<0.01). There was no apparent pharmaco-to be of importance in CsA induced hypertension. kinetic interaction between the b-blockers and CsA However, in these studies the vasoconstrictor effects of since whole blood CsA trough levels remained stable CsA could not be clarified completely since only partial during the whole study period. The means of these improvement in renal haemodynamics was achieved trough levels were 187±33 and 160±40 ng/ml during [18] . Whatever the mechanisms of both drugs are, treatment with atenolol and tertatolol respectively, and from our data it is evident that tertatolol is not able 152±48 ng/ml during the wash-out period.
to attenuate the vasoconstrictor effect of CsA. At first sight, our data also seem to be in contrast to the observations with carvedilol in a comparable group of Discussion renal transplant recipients [19] . In that study, the b 1 -selective agent metoprolol and the non-selective carvedilol had comparable effects on blood pressure but only In our transplant recipients on CsA, both atenolol and tertatolol effectively reduced blood pressure without carvedilol induced renal vasodilation. However, this renal effect could be easily explained by the a l -adrenonegatively influencing renal function. This makes these drugs with their well-known cardioprotective effects ceptor blocking property of carvedilol which is lacking in tertatolol.
[14] an attractive choice for this category of patients with a high prevalence of cardiovascular disease. To
Despite the effectiveness of b-blockers as shown in the present study, CEBs still are the best suitable drugs the best of our knowledge, this effectiveness of bblockers in renal transplant recipients on CsA has not in the treatment of CsA induced hypertension in patients on CsA. Besides their blood pressure lowering been clearly demonstrated before and could seem somewhat surprising in view of the limited role of effects, CEBs counteract the CsA induced reduction of GFR and RPF and acutely even cause natriuresis the renin-angiotensin system ( RAS) in CsA-induced hypertension in humans. In contrast to animal studies, during the use of CsA [6, 20] . These favourable effects of CEBs during CsA are to be ascribed to their CsA administration in humans does not stimulate the RAS and even can suppress it [1] . Increased sympath-vasodilatory action on resistance arterioles, and, with respect to their renal actions, largely on the specific etic nerve activity and increase of intravascular volume seem to play a more important role in CsA-induced vasodilation of afferent arterioles. When combining CsA and a calcium entry blocker one must realize that hypertension [15] .
Our study does not allow a conclusion on superiority some CEBs interfere with the metabolism of CsA, thus necessitating a CsA-dose reduction [21] . Other importof tertatolol over atenolol in CsA treated hypertensive patients, since the effects of both drugs were compar-ant problems during treatment with CEBs are their earlier mentioned side-effects. Indeed, many of these able. Of note, we did not find any indication for a renal vasodilatory effect of tertatolol in these patients side-effects, such as palpitations and headache, can be counteracted by b-blockers. This means that b-blockers in contrast to other observations with this drug in both patients with essential hypertension and patients with are not only suitable as monotherapy but also very useful in combination with CEBs. moderate renal failure [10] [11] [12] . In these previous studies it was suggested that in addition to its b-blocker Although the present study does not allow firm conclusions due to the low number of patients, the properties tertatolol had specific vasodilatory effects operating at both the afferent and efferent arteriole, data seem to confirm our previous studies [22, 23] in which we demonstrated that the antihypertensive efficausing an increase in GFR and RPF without influen-beta-adrenoceptor blocking drugs. Am J Hem 1989; 2:
cacy of b-blockers was more pronounced in patients 237S-240S with glomerulonephritis as their original disease than 10. Hannedouche T, Brouard R, Godin M, Kleinknecht D, Paillard in patients with other renal diseases. Previously, we 
